Skip to Content Facebook Feature Image

SHL Medical opens new US$220 million manufacturing facility in the US to serve growing autoinjector market

Business

SHL Medical opens new US$220 million manufacturing facility in the US to serve growing autoinjector market
Business

Business

SHL Medical opens new US$220 million manufacturing facility in the US to serve growing autoinjector market

2025-04-01 16:00 Last Updated At:16:15

ZUG, Switzerland, April 1, 2025 /PRNewswire/ -- SHL Medical, a global leader in the design, development, and manufacturing of advanced self-injection solutions, has officially inaugurated its new state-of-the-art manufacturing facility in North Charleston, South Carolina. This strategic expansion marks a significant milestone in the Swiss-based company's global growth, reinforcing its commitment to meeting the increasing worldwide demand for autoinjectors, most notably used in the cardiometabolic sector.

The new facility will manufacture SHL Medical's industry-leading autoinjectors, which are used in some of the world's best-selling medications in areas such as endocrine and metabolic disorders (including GLP-1 therapies), dermatology, musculoskeletal diseases, and other therapy areas. It ensures a reliable supply of these critical devices to millions of patients worldwide.  

Strengthening production capacity and US market presence

SHL Medical is significantly increasing its production capacity to meet growing demand in North America while strengthening supply chain resilience. "US-based production is a major step forward in our global expansion and reinforces our position as the leader in providing end-to-end drug delivery solutions," said Ulrich Faessler, CEO & Chairman of SHL Medical. "With our established site in Taiwan and the upcoming facility in Switzerland, we will be the only autoinjector manufacturer operating across three continents, bringing us even closer to our customers."

The fully automatized 360,000 ft²facility represents a US$220 million investment and has already created over 300 local jobs, contributing to the economic growth of the region. Equipped with cutting-edge medical device injection molding technology and fully automated assembly capabilities, the site ensures unmatched precision, efficiency, and quality in SHL Medical's advanced drug delivery solutions.

By leveraging its existing final assembly, labeling, and packaging operations in Deerfield Beach, Florida, and integrating recent acquisitions under SHL Advantec, the North Charleston facility enhances SHL Medical's US presence and solidifies its leadership in large-scale autoinjector production. The company is on track to deliver 1.5 billion devices to customers in 2025.

"The most trusted autoinjector brand is now made in the USA. We are proud to be contributing to the growth of the local economy and becoming a key player in the area while contributing to our sustainability goals." adds Kimberlee Steele, Managing Director North America at SHL Medical.

The Grand Opening event, attended by approximately 180 guests, including South Carolina's Governor Henry McMaster and Swiss Embassy Consul General Urs Broennimann, marked the official opening of SHL Medical's innovative autoinjector production in the United States.

For more detailed information about SHL's latest expansion strategy, please refer to the press releases below:

New manufacturing site in Zug, Switzerland

New manufacturing site in North Charleston, NC, USA

SHL Medical announces plans to establish SHL Advantec

SHL Medical acquires Swiss toolmaking company SMC Mould Innovation

SHL Medical further strengthens vertical capabilities with the acquisition of US manufacturer Superior Tooling Inc.

SHL Medical acquires 100% of the shares in Swiss company LCA Automation

About SHL Medical

SHL Medical is a pioneering leader in self-injection solutions, such as autoinjectors. Driven by our core purpose of "enabling patients' independence", we partner with leading pharma and biotech companies to develop self-injection systems and digital solutions enhance patients' treatment experience and quality of life. With over 5,000 employees located across our offices in Switzerland, USA, Sweden, and Taiwan, we rely on our comprehensive in-house manufacturing capabilities to provide end-to-end services, from design, development, to final assembly, labeling, and packaging. For additional information, visit www.shl-medical.com

Global Media Contact

Burson Switzerland
shl-pressoffice@bcw-global.com

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

SHL Medical opens new US$220 million manufacturing facility in the US to serve growing autoinjector market

SHL Medical opens new US$220 million manufacturing facility in the US to serve growing autoinjector market

MONROE, N.J. and RANCHO CUCAMONGA, Calif., May 9, 2026 /PRNewswire/ -- MimiSilk, the clinical-grade at-home beauty device brand, launched its 2026 Mother's Day campaign, offering a limited-time promotion across its full product collection. The campaign aims to provide consumers with accessible, professional skincare solutions as a gifting choice for the holiday, offering mothers a way to experience medical-grade skin rejuvenation from the comfort of home.

About MimiSilk: Silk Your Skin, Love Your Glow

MimiSilk was founded on a clear mission: to make clinical-grade skincare part of everyday life — offering an effective standalone solution for those seeking skin rejuvenation at home, and a powerful complement to in-clinic treatments for long-term maintenance and lasting results. Its devices are designed to be safe, accessible, and built into daily life – supporting women in building consistent self-care habits that help soften visible signs of aging, restore a natural inner glow, and achieve a texture as smooth as silk. At the core of the brand is a simple belief: beauty is about confidence, control, and taking time to care for yourself.

MimiSilk Iris: Multi-Benefit Anti-Aging in One Device

The flagship product of this season's campaign is the MimiSilk Iris, a non-ablative fractional laser device for at-home use. Operating at a clinically proven 1450 nm wavelength, Iris stimulates natural collagen production to address the appearance of wrinkles, refine pore visibility, and improve overall skin radiance. The device is non-invasive and requires no recovery downtime, making it compatible with a standard nightly skincare routine.

A Limited-Time Mother's Day 2026 Offer

The Mother's Day promotion is available across MimiSilk's collection, catering to both individual consumers and gift shoppers, making it a practical gifting choice for those looking to offer a practical, results-oriented skincare solution.

MimiSilk believes skincare can be more than a beauty step — it can be a meaningful part of how women feel refreshed, confident, and cared for in daily life. A few focused moments each week can become a quiet ritual of restoration and self-care. This Mother's Day and beyond, the brand hopes mothers everywhere feel seen, appreciated, and beautifully radiant.

Further details on the campaign and products are available on the MimiSilk official website.

 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

MimiSilk Celebrates Mother's Day 2026: The Gift of Skin Confidence

MimiSilk Celebrates Mother's Day 2026: The Gift of Skin Confidence

Recommended Articles